Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.

Krishnan B, Torti FM, Gallagher PE, Tallant EA.

Prostate. 2013 Jan;73(1):60-70. doi: 10.1002/pros.22540. Epub 2012 May 29.

PMID:
22644934
2.

Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE.

Prostate. 2013 Jan;73(1):71-82. doi: 10.1002/pros.22542. Epub 2012 May 29.

3.

Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.

Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA.

Mol Cancer Ther. 2009 Jun;8(6):1676-83. doi: 10.1158/1535-7163.MCT-09-0161. Epub 2009 Jun 9.

4.

Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.

Pei N, Wan R, Chen X, Li A, Zhang Y, Li J, Du H, Chen B, Wei W, Qi Y, Zhang Y, Katovich MJ, Sumners C, Zheng H, Li H.

Mol Cancer Ther. 2016 Jan;15(1):37-47. doi: 10.1158/1535-7163.MCT-14-0981. Epub 2015 Dec 15.

5.

Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.

Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE.

Cancer Res. 2007 Mar 15;67(6):2809-15.

6.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

7.

Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study.

Anton L, Merrill DC, Neves LA, Gruver C, Moorefield C, Brosnihan KB.

Reprod Biol Endocrinol. 2010 Nov 4;8:135. doi: 10.1186/1477-7827-8-135.

8.

PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.

Zins K, Kovatchki D, Lucas T, Abraham D.

Int J Mol Sci. 2016 Sep 23;17(10). pii: E1613. doi: 10.3390/ijms17101613.

9.

Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.

Taylor AP, Osorio L, Craig R, Raleigh JA, Ying Z, Goldenberg DM, Blumenthal RD.

Clin Cancer Res. 2002 Apr;8(4):1213-22.

10.

Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.

Tesan T, Gustavsson H, Welén K, Damber JE.

BJU Int. 2008 Sep;102(8):1034-9. doi: 10.1111/j.1464-410X.2008.07768.x. Epub 2008 May 16.

11.
12.

Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts.

Zins K, Thomas A, Lucas T, Sioud M, Aharinejad S, Abraham D.

Int J Mol Sci. 2013 Sep 3;14(9):17958-71. doi: 10.3390/ijms140917958.

13.

Placental growth factor upregulation is a host response to antiangiogenic therapy.

Bagley RG, Ren Y, Weber W, Yao M, Kurtzberg L, Pinckney J, Bangari D, Nguyen C, Brondyk W, Kaplan J, Teicher BA.

Clin Cancer Res. 2011 Mar 1;17(5):976-88. doi: 10.1158/1078-0432.CCR-10-2687. Epub 2011 Feb 22.

14.

Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.

Bagley RG, Ren Y, Kurtzberg L, Weber W, Bangari D, Brondyk W, Teicher BA.

Int J Oncol. 2012 Feb;40(2):479-86. doi: 10.3892/ijo.2011.1257. Epub 2011 Nov 10.

PMID:
22075622
15.

G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.

Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR.

Tohoku J Exp Med. 2012 Oct;228(2):147-56.

16.
17.

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.

Torimura T, Iwamoto H, Nakamura T, Abe M, Ikezono Y, Wada F, Sakaue T, Masuda H, Hashimoto O, Koga H, Ueno T, Yano H.

Neoplasia. 2016 Jul;18(7):413-24. doi: 10.1016/j.neo.2016.05.001.

18.

Bcl-2 mediated modulation of vascularization in prostate cancer xenografts.

Sakai Y, Goodison S, Kusmartsev S, Fletcher B, Eruslanov E, Cao W, Porvasnik S, Namiki K, Anai S, Rosser CJ.

Prostate. 2009 Apr 1;69(5):459-70. doi: 10.1002/pros.20888.

PMID:
19107861
19.

1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB, Liu M.

Carcinogenesis. 2011 Jun;32(6):904-12. doi: 10.1093/carcin/bgr052. Epub 2011 Mar 22.

20.

The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.

Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ.

Int J Cancer. 2006 Oct 1;119(7):1519-29.

Supplemental Content

Support Center